AML (IDH2-Mutant) Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About AML (IDH2-Mutant)
Acute Myeloid Leukemia (AML) with an IDH2 mutation is a distinct subtype of blood cancer requiring specialized treatment. This genetic marker influences disease progression and therapeutic approaches. While targeted therapies offer new hope, the cost of these life-saving medications can be a significant burden. TheDrugClub helps individuals and families manage these expenses, ensuring access to vital prescriptions.
Acute Myeloid Leukemia (AML) is a fast-growing cancer that affects the blood and bone marrow, leading to an overproduction of abnormal white blood cells. While AML can manifest in various forms, a specific subtype, known as AML IDH2 mutant, is characterized by a mutation in the isocitrate dehydrogenase 2 (IDH2) gene. This genetic alteration is found in approximately 8-19% of AML patients and plays a crucial role in the disease's development and progression.
The IDH2 mutation leads to the production of an oncomet
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.